Objectives: The present study aimed to evaluate the outcome and potential limitations of a repeated MitraClip procedure (ReClip).
Background:
The MitraClip procedure has emerged as a treatment option in high surgical risk patients suffering from severe mitral regurgitation (MR). However, despite successful initial repair a significant number of patients develops severe recurrent MR.
Methods: Patients undergoing a ReClip procedure in our institution were retrospectively identified. Baseline data and the procedural outcome were assessed to identify potential limitations of such procedures.
Results: Fifteen out of 234 patients undergoing a mitral-valve repair with the MitraClip device (Abbott Vascular) underwent a ReClip due to recurrent MR. In 11 patients, a MR reduction of at least one degree without causing mitral valve stenosis (trans-mitral mean gradient ≥5 mmHg) was achieved by performing a ReClip. After 1 year, two patients developed severe recurrent MR again. Pulmonary artery pressures significantly decreased after the procedure in individuals with successful repair (MR reduction of at least one degree and mitral valve mean gradient <5 mmHg).
Conclusion:
A ReClip procedure may be feasible in patients with recurrent MR but the risk benefit ratio should be carefully balanced against other treatment options.
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| INTRODUCTION
Mitral Regurgitation (MR) is one of the most common valvular heart diseases in Europe and Northern America, affecting almost 10% of the population aged 75 years or older. 1, 2 The MitraClip device (Abbott Vascular, Menlo Park, CA), which mimics the surgical edge-to-edge repair, offers a trans-catheter treatment strategy to patients who are inoperable or at high surgical risk. [3] [4] [5] [6] According to the EVEREST II trial this approach has proven superiority in terms of patient safety, combined with similar symptomatic benefit when compared to mitral valve surgery. 7 However, there are a number of patients who experience a deterioration of their mitral valve function even after successful initial repair. 8 The feasibility of a repeated MitraClip procedure (ReClip) is therefore an important question. Although this matter has been commented on in several trials and registry studies, published literature is mainly limited to case reports. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Kreidel et al published a small series, but included patients irrespective of the initial result of the first procedure.
Hence, in this retrospective study we aimed to assess the outcome and potential limitations of ReClip procedures in patients with recurrent MR after initial successful percutaneous repair.
2 | METHODS
| Patient population
In total 234 MitraClip procedures were performed in our institution between November 2010 and July 2016. We retrospectively identified 22 patients with recurrent MR following a successful first intervention. In 15 of these patients suffering from worsening heart failure (HF) symptoms due to recurrent severe MR a ReClip procedure was performed. According to guideline recommendations all of these patients were suffering from severe MR and were judged inoperable or at high surgical risk. 6 The outcome of the ReClip procedure was classified successful if MR reduction of ≥1 grade was achieved while the MVG at discharge was <5 mmHg at a controlled heart rate (60-90 bpm). The study was approved by the local ethics committee.
| Patient selection and pre-procedural management
HF medications were optimized in all patients before mitral valve intervention was considered. Only patients with persistent HFsymptoms and severe MR were further evaluated and discussed in an interdisciplinary heart team meeting before the procedure.
Preprocedural transesophageal and transthoracic echocardiograms were performed in all patients to assess MR severity, the underlying MR pathology and mitral valve morphology. Patients were deemed eligible for percutaneous edge-to-edge repair based on surgical risk, estimated with the Society of Thoracic Surgeons' risk score (STS score)
as well as anatomical feasibility criteria as published previously. 9, [20] [21] [22] Patients with a resting gradient (at a heart rate of 60-90 bpm) of 5 mmHg or more were precluded from a ReClip intervention.
Anticoagulation was discontinued at least 24 h before the procedure and an international normalized ratio (INR) of <2 was required. Antibiotic prophylaxis was administered before every procedure.
| Intra-and post-procedural management
All MitraClip procedures were performed under general anesthesia.
Transesophageal echocardiography (TOE) and fluoroscopy were used to guide the interventions. Access was performed from the right femoral vein in all cases. After successful transseptal puncture intravenous heparin was administered in order to achieve an activated clotting time between 250 and 350 s. The procedure was then executed as previously described. 7 Patients who were not on oral anticoagulation were treated with 100 mg of aspirin per day for at least 6 months combined with 75 mg of clopidogrel per day for 1 month after the procedure. In Patients with an indication for oral anticoagulation, this medication was continued without adding any antiplatelets. TOE studies were performed at baseline of both procedures to evaluate the valve pathology and to exclude intracardiac thrombus formations. MR was defined as degenerative in the presence of structural changes causing significant regurgitation.
| Echocardiographic assessment
Functional MR was defined as abnormal functioning structurally normal leaflets, in the context of impaired LV-function, resulting from ischemic heart disease or dilated cardiomyopathy. Regarding the pathophysiology of recurrent MR after the first procedure, particular attention was payed to leaflet insertion (LI) and loss of leaflet insertion (LLI), new pathologies of the mitral leaflets or progressive annulus dilatation. Therefore, baseline
TEEs before the Reclip were compared to intraprocedural images taken at the time of the first procedure.
The amount of leaflet material grasped by the clip (LI) and loss of leaflet insertion (LLI) during follow up, were defined in all patients. 19 The measurements were taken in an LVOT view, the image plane selected just next to the implanted clip. LI was then measured from the deflection point to the tip of the leaflet ( Figure 1 ).
LLI was defined as loss of leaflet material at baseline of the ReClip procedure, combined with increasing mobility of the implanted Clip (compared to the intraprocedural TOE images taken during the first procedure) and the exclusion of a prolapse/flail as cause of this mobility.
Partial clip detachment (PCD) was diagnosed when LI of one of the leaflets was lost completely.
| Statistical analysis
Continuous variables are depicted as median and Interquartile Range (IQR). All categorical variables are stated as number of individuals (n) and percentage. Groups were compared using Wilcoxon and chisquared test. Subgroups were compared using Mann-Whitney-U test.
P values of <0.05 were considered to be statistically significant. The statistical analysis was performed using SPSS version 23 for Mac OS (IBM SPSS Statistics, Armonk, NY: IBM Corp.).
3 | RESULTS
| Patient characteristics at baseline
Baseline characteristics of the two procedures are depicted in Table 1 .
At baseline of the first procedure MR was classified as functional in eight and degenerative in seven patients, whereas prolapse of the anterior and the posterior leaflets were present in three individuals, respectively. Combined AML and PML prolapse was found in another patient. Seven patients (47%) showed LLI at baseline of the ReClip procedure, including two patients with PCD.
The increase of the STS score from the first to the ReClip procedure was driven not only by characterizing the ReClip as a reoperation in its calculation but also by worsening of the individual patientś heart function, potential other heart valve diseases and renal function.
3.2 | Procedure characteristics and outcome after the 1st and 2nd procedure
The median time between both procedures was 441.0 (187.0-814.0) days.
The first intervention was successfully performed in all patients, whereas procedural success of the ReClip was achieved in eleven patients.
MR recurrence due to LLI after the first procedure was identified in seven patients. No specific pathology was observed in the other patients. The characteristics of both procedures are shown in Table 2 . Pulmonary artery pressures (PAP) significantly declined after both procedures (P = 0.011 after the first and P = 0.004 after the second procedure). Comparing the failed and successful ReClip procedures, PAP only improved in the latter group (−10 (−13.0 to −9.0) mmHg, P = 0.042 vs −2 (−11.0-4.0) mmHg, P = 0.663) (Table 3 ). Median MR improvement was consistent during the 1-year follow-up after the ReClip intervention (Figure 2 ), although two patients developed severe recurrent MR within this time frame despite initial successful repair. One of these two patients underwent surgical mitral valve replacement. Therefore, 1 year after ReClip, 9 out of 15 patients (60%) were left with a good technical result.
We did not observe any procedure related complications, neither during the first nor during the ReClip intervention.
| Factors influencing the technical outcome of the ReClip procedure
The subgroup analysis of patients with either successful or unsuccessful ReClip procedure is shown in Table 3 .
The cause of failure was insufficient MR reduction in two patients and increased MVG in one patient (6.29 mmHg). In another patient, the A trend toward worse results in patients with a higher MVG and a shorter coaptation depth after the first intervention was observed (Table 3) .
| Loss of leaflet insertion
According to our definition, seven patients (47%) were diagnosed with LLI including two with PCD at baseline of the ReClip procedure. Two patients experienced LLI at AML only, three patients at PML only and two patients showed LLI at both leaflets. The time to ReClip was significantly shorter in patients with LLI (6.2 vs 18.6 months in patients without LLI, P = 0.037). Furthermore, patients with LLI were significantly older (P = 0.026). Morphological criteria as mentioned in Table 4 were not significantly different in the LLI and the no LLI groups. The presence of LLI was not associated with the outcome of the ReClip intervention (OR = 1.2, CI 0.121-11.865, P = 0.876).
In the no LLI group no specific modes of failure could be identified.
Especially no leaflet perforations were found. identifying the exact mechanism of MR may be difficult in some patients.
A previous study by Kreidel et al found worse results after ReClip when LLI was the cause of recurrent MR. 19 Interestingly, this association was not observed in our cohort, which may be due to different methods applied to define LLI. While leaflet insertion was measured in a TOE LVOT view, the plane aligned just next to the clip in our study, Kreidel et al calculated LLI based on measurements taken from transthoracic echocardiograms performed before and after the first procedure. 19 In our opinion, these calculations may be inaccurate,
as it presumes that all measurements are taken in the same plane.
Furthermore, the LLI definition in our study was based on three different criteria, taking also into account clip mobility during the first and at baseline before the second procedure (as mentioned in our methods). Applying these criteria in combination with the described measurement technique in our patients LI values of 4.2 mm in the LLI and 6.1 mm in the no LLI group were found at baseline of the ReClip procedure.
Among several parameters, patient age was the only predictor for LLI in our study. Although we did not find any associations between LLI and morphological criteria, progressive degenerative processes like leaflet thickening and calcification may be discussed in this context.
As indicated by the significantly shorter inter-procedural time period in the LLI compared to the no LLI group, this complication may be expected early after MitraClip.
A declining PAP, which is often interpreted as a surrogate for successful mitral valve repair, was observed in patients who experienced a MR reduction of at least one degree in combination with a trans-mitral mean gradient of less than 5 mmHg. Patients who did not fulfil these criteria did not show a significant improvement of pulmonary hypertension after the ReClip procedure.
Although increased trans-mitral gradients were the cause of failure in only two of our patients, we think the degree of mitral-valve stenosis following percutaneous repair should be considered to define optimal results.
Overall, we did not find any significant predictors for worse technical outcome of a ReClip intervention, which may be due to the limited number of patients; however, shorter coaptation depth and higher MVG were of borderline significance and should be investigated in larger cohorts. 
| Limitations
Beside the retrospective nature of our study, the limited number of patients is the most important limitation. This may explain why many trends but only a few statistically significant results were observed.
Furthermore, there is currently no consistent definition of procedural success and LLI available in the literature. The highly preselected patient cohort also has to be considered when interpreting the results.
| CONCLUSIONS
The low number of complications of the MitraClip procedure, which has been demonstrated in various studies, may justify a ReClip intervention in carefully selected patients. However, the risk benefit ratio should be carefully balanced against other treatment options.
Shorter coaptation depth and higher MVG after the first procedure may account for worse ReClip results. Larger studies are needed to confirm these results.
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